ZA939457B - Compounds - Google Patents

Compounds

Info

Publication number
ZA939457B
ZA939457B ZA939457A ZA939457A ZA939457B ZA 939457 B ZA939457 B ZA 939457B ZA 939457 A ZA939457 A ZA 939457A ZA 939457 A ZA939457 A ZA 939457A ZA 939457 B ZA939457 B ZA 939457B
Authority
ZA
South Africa
Prior art keywords
pct
compounds
date jul
sec
formula
Prior art date
Application number
ZA939457A
Other languages
English (en)
Inventor
Gary Thomas Borrett
John Kitteringham
Roderick Alan Porter
Mark Ralph Shipton
Mythily Vimal
Rodney Christopher Young
Original Assignee
Smithkline Beecham Plc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smithkline Beecham Plc filed Critical Smithkline Beecham Plc
Publication of ZA939457B publication Critical patent/ZA939457B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
ZA939457A 1992-12-21 1993-12-17 Compounds ZA939457B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB929226530A GB9226530D0 (en) 1992-12-21 1992-12-21 Compounds

Publications (1)

Publication Number Publication Date
ZA939457B true ZA939457B (en) 1995-06-19

Family

ID=10726909

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA939457A ZA939457B (en) 1992-12-21 1993-12-17 Compounds

Country Status (18)

Country Link
US (2) US5618947A (es)
EP (1) EP0674621B1 (es)
JP (1) JP3364222B2 (es)
KR (1) KR100307001B1 (es)
CN (1) CN1039491C (es)
AT (1) ATE233239T1 (es)
AU (1) AU688748B2 (es)
CA (1) CA2152630C (es)
DE (1) DE69332718T2 (es)
DK (1) DK0674621T3 (es)
ES (1) ES2193151T3 (es)
GB (1) GB9226530D0 (es)
HK (1) HK1012368A1 (es)
MX (1) MX9400035A (es)
NZ (1) NZ259363A (es)
PT (1) PT674621E (es)
WO (1) WO1994014772A1 (es)
ZA (1) ZA939457B (es)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5616603A (en) * 1995-05-26 1997-04-01 Smithkline Beecham Plc Enantiomers of carbazole derivatives as 5-HT1 -like agonists
US5917054A (en) * 1995-07-18 1999-06-29 Smithkline Beecham P.L.C. Process for preparing enantiomers of carbazole derivatives as 5-HT1 -like agonists
GB9706089D0 (en) * 1997-03-24 1997-05-14 Scherer Ltd R P Pharmaceutical composition
GB9723061D0 (en) * 1997-10-31 1998-01-07 Vanguard Medica Ltd Medicaments
EP1043991A4 (en) * 1997-11-14 2005-02-02 Lilly Co Eli TREATMENT OF ALZHEIMER DISEASE
GB9808069D0 (en) * 1998-04-16 1998-06-17 Vanguard Medica Ltd Novel processes
GB9817911D0 (en) * 1998-08-17 1998-10-14 Vanguard Medica Ltd New use
FR2841899A1 (fr) * 2002-07-05 2004-01-09 Ppg Sipsy Procede de resolution asymetrique d'un racemique faisant intervenir l'acide diprogulique et utilisation dudit acide comme agent de resolution asymetrique
BRPI0608353A2 (pt) * 2005-02-17 2009-12-01 Wyeth Corp derivados de indol, benzotiofeno, benzofurano e indeno cicloalquilfundidos
US20090069399A1 (en) * 2007-09-12 2009-03-12 Protia, Llc Deuterium-enriched frovatriptan
WO2010073253A1 (en) * 2008-12-22 2010-07-01 Natco Pharma Limited Method for preparing an optically active frovatriptan
WO2010122343A1 (en) * 2009-04-23 2010-10-28 Generics [Uk] Limited A process for the preparation of frovatriptan and frovatriptan succinate and their synthetic intermediates
WO2011095803A1 (en) * 2010-02-02 2011-08-11 Generics [Uk] Limited Hplc method for analyzing frovatriptan
WO2012147020A1 (en) * 2011-04-25 2012-11-01 Orchid Chemicals And Pharamceuticals Limited An improved process for the preparation of frovatriptan
EP2816030A1 (en) * 2013-06-20 2014-12-24 Duke Chem, S. A. Process for the preparation of frovatriptan and its enantiomer
GB201312768D0 (en) * 2013-07-17 2013-08-28 Ge Healthcare Ltd Work-up procedure
CN104402798B (zh) * 2014-10-21 2016-09-14 杭州瑞德化工有限公司 一种3-氨基-1，2，3，4-四氢咔唑的拆分方法
CN104529871A (zh) * 2014-12-22 2015-04-22 青岛正大海尔制药有限公司 一种琥珀酸呋罗曲坦的制备方法
US11405689B2 (en) * 2020-12-09 2022-08-02 Rovi Guides, Inc. Systems and methods for providing recording of a blacked-out media content item

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4257952A (en) * 1977-06-06 1981-03-24 Sterling Drug Inc. 3-Amino-tetrahydrocarbazoles
JPS6429699A (en) * 1987-07-24 1989-01-31 Mitsubishi Heavy Ind Ltd Recovery method for adiabatic compression heat
US4874399A (en) * 1988-01-25 1989-10-17 Minnesota Mining And Manufacturing Company Electret filter made of fibers containing polypropylene and poly(4-methyl-1-pentene)
JPH0247924A (ja) * 1988-08-08 1990-02-16 Nec Corp 分周回路
GB9113802D0 (en) * 1991-06-26 1991-08-14 Smithkline Beecham Plc Medicaments

Also Published As

Publication number Publication date
KR950704253A (ko) 1995-11-17
ES2193151T3 (es) 2003-11-01
DK0674621T3 (da) 2003-06-10
AU688748B2 (en) 1998-03-19
WO1994014772A1 (en) 1994-07-07
MX9400035A (es) 1994-07-29
HK1012368A1 (en) 1999-07-30
DE69332718T2 (de) 2003-12-04
CA2152630A1 (en) 1994-07-07
US5650426A (en) 1997-07-22
CN1039491C (zh) 1998-08-12
GB9226530D0 (en) 1993-02-17
JP3364222B2 (ja) 2003-01-08
US5618947A (en) 1997-04-08
KR100307001B1 (ko) 2001-12-28
EP0674621B1 (en) 2003-02-26
CN1095712A (zh) 1994-11-30
AU5814594A (en) 1994-07-19
DE69332718D1 (de) 2003-04-03
NZ259363A (en) 1996-12-20
JPH08504790A (ja) 1996-05-21
PT674621E (pt) 2003-07-31
EP0674621A1 (en) 1995-10-04
ATE233239T1 (de) 2003-03-15
CA2152630C (en) 2005-07-26

Similar Documents

Publication Publication Date Title
ZA939457B (en) Compounds
IL104740A0 (en) Hypolipidaemic compounds,their preparation and pharmaceutical compositions containing them
GB9114948D0 (en) Process for preparing sertraline intermediates
IL108520A0 (en) Imidazopyridine derivatives, processes for the preparation thereof, and pharmaceutical compositions containing them
GB9121456D0 (en) Triazole antifungal agents
ES8303402A1 (es) Un procedimiento para preparar un compuesto anti-hipertension.
HU9402466D0 (en) Indole derivatives as steroid-5-alpha-reductase inhibitors
GR3017766T3 (en) Process for preparing sertraline.
GB9405492D0 (en) Chemical compounds
ATE161178T1 (de) Pyrazolpyridine für die behandlung der anämie
FI913713A0 (fi) Nya bicykliska aminosubstituerade foereningar.
GR3021736T3 (en) N-substitued 3-azabicyclo 3.2.0]heptane derivatives useful as neuroleptic agents etc.
GR3030506T3 (en) 1-azaadamantane derivatives as 5-ht agonists or antagonists.
HUT65218A (en) Process for preparing n-[(4,5-dihydroxi- and 4,5,8-trihydroxi-9,10-dihydro-9,10-dioxo-2-anthracene-yl)carbonyl]amino acids and pharmaceutical compositions containing them as active agent
TW261605B (es)
HUT53103A (en) Process for the preparation of new 20,21-dinor-eburnamenine derivatives, new intermediates thereof, as well as pharmaceutical compositions containing said compounds as active ingredients
IL99777A0 (en) Indole derivatives,processes for their preparation and pharmaceutical compositions containing them
GR3000773T3 (en) 2,2;6,6-diethylene-3-oxo-17-alpha-pregn-4-ene-21,17-carbolactones, process for their preparation and pharmaceutical compositions containing them
GR3024366T3 (en) INDOLE DERIVATIVES AS STEROID 5-g(a)-REDUCTASE INHIBITORS